Publications by authors named "Hiromi Nishiba"
Article Synopsis
- Opioids, which are commonly used for pain relief, often cause constipation, particularly in older adults—this study focuses on a treatment for that issue called naldemedine for patients over 75 with cancer.* -
- The researchers analyzed medical records from 10 hospitals in Japan, studying 60 cancer patients who were hospitalized for at least a week before and after starting naldemedine.* -
- Results showed a 68.3% response rate in increasing bowel movements, with diarrhea being the most frequent side effect, mostly mild, indicating that naldemedine is both effective and safe for older cancer patients dealing with opioid-induced constipation.*
Article Synopsis
- * The study retrospectively tracked 33 patients with various gastrointestinal cancers in Japan who were treated with naldemedine, focusing on their defecation frequency before and after starting the medication.
- * Results showed a 63.6% response rate, with significant increases in bowel movements after naldemedine use; most patients reported minor gastrointestinal side effects, indicating that naldemedine is generally safe and effective for managing OIC in these cancer patients.
: Opioid analgesics, which are used for cancer-related pain management, cause opioid-induced constipation (OIC). Naldemedine, a peripheral opioid receptor antagonist, is an OIC-modifying agent, but no focused efficacy and safety analysis has been conducted for its use in hepatobiliary pancreatic cancers. We performed a multi-institutional study on the efficacy and safety of naldemedine in patients with hepatobiliary pancreatic cancer using opioids in clinical practice.
View Article and Find Full Text PDFConstipation is a concern among patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 and 4. To assess naldemedine's efficacy and safety in cancer patients on opioids with poor PS. Multicenter, retrospective study.
View Article and Find Full Text PDFBackground: We conducted a multicenter, retrospective study on the efficacy and safety of naldemedine in thoracic cancer patients using opioids in clinical practice.
Methods: We retrospectively evaluated thoracic cancer patients treated with naldemedine at 10 institutions in Japan. Clinical data of patients administered naldemedine between June 2017 and August 2019 were extracted from electronic medical records.
The efficacy and safety of naldemedine for opioid-induced constipation in patients with cancer has not been investigated in clinical practice. We conducted a multicenter, retrospective study to assess the effects of naldemedine among 10 Japanese institutions between June 2017 and August 2019. We evaluated the number of defecations 7 days before and after naldemedine administration.
View Article and Find Full Text PDF: Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves opioid-induced constipation. Although clinical trials have excluded patients with poor performance status (PS) and those started on naldemedine early after opioid initiation, clinical practice has used naldemedine for the same patients. Therefore, we investigated the treatment patterns of naldemedine in a real-world setting.
View Article and Find Full Text PDF